{"id":702487,"date":"2022-10-28T07:45:25","date_gmt":"2022-10-28T11:45:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/"},"modified":"2022-10-28T07:45:25","modified_gmt":"2022-10-28T11:45:25","slug":"medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/","title":{"rendered":"Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">TORONTO and HOUSTON, Oct.  28, 2022  (GLOBE NEWSWIRE) &#8212; Medicenna Therapeutics Corp. (&#8220;Medicenna&#8221; or \u201cthe Company&#8221;) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that on October 25, 2022, it received a notice (the \u201cNotice\u201d) from the Nasdaq Stock Market LLC (\u201cNasdaq\u201d), stating that the Company is not in compliance with the minimum bid price requirement (&#8220;Minimum Bid Requirement&#8221;) of US$1.00 per share under the Nasdaq Listing Rule 5450(a)(1) based upon the closing bid price of the Company\u2019s common stock for the 30 consecutive business days prior to the date of the Notice. The Notice has no immediate effect on the listing or trading of the Company\u2019s common stock on Nasdaq, and the Company\u2019s operations are not affected by the receipt of the Notice.<\/p>\n<p align=\"justify\">Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days from the date of the Notice, or until April 24, 2023, to regain compliance with the Minimum Bid Requirement, during which time the Company\u2019s common stock will continue to trade on Nasdaq. If at any time before April 24, 2023, the bid price of Medicenna common shares closes at or above US$1.00 per share for a minimum of 10 consecutive business days, the Company will regain compliance with the Minimum Bid Requirement. If the Company does not regain compliance with the Minimum Bid Requirement by April 24, 2023, the Company may be eligible, upon satisfaction of certain Nasdaq listing requirements, for an additional period of 180 calendar days to regain compliance or its common stock may be subject to delisting from Nasdaq.<\/p>\n<p align=\"justify\">The Company will closely monitor the closing bid price of its common stock and is considering its options to regain compliance with the Minimum Bid Requirement under the Nasdaq Listing Rules. This notice does not have any impact on the Company\u2019s TSX listing.<\/p>\n<p align=\"justify\">\n        <strong>About Medicenna<\/strong>\n      <\/p>\n<p align=\"justify\">Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna&#8217;s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna\u2019s early-stage BiSKITs\u2122 program, (<strong>Bi<\/strong>functional\u00a0<strong>S<\/strong>uper<strong>K<\/strong>ine<strong>\u00a0I<\/strong>mmuno<strong>T<\/strong>herapie<strong>s<\/strong>)\u00a0is designed to enhance the ability of Superkines to treat immunologically \u201ccold\u201d tumors. Medicenna&#8217;s IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA\/EMA, respectively.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This news release contains forward-looking statements under applicable securities laws and relate to the future operations of the Company and other statements that are not historical facts including, but not limited to, statements related to the extension of the term of the Warrants. Forward-looking statements are often identified by terms such as \u201cwill\u201d, \u201cmay\u201d, \u201cshould\u201d, \u201canticipate\u201d, \u201cexpects\u201d, \u201cbelieves\u201d, \u201cseeks\u201d and similar expressions. All statements other than statements of historical fact, included in this release, are forward-looking statements that are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company\u2019s expectations include the risks detailed in the annual information form and Form 20-F of the Company and in other filings made by the Company with the applicable securities regulators from time to time in\u00a0Canada\u00a0and\u00a0the\u00a0United States.<\/p>\n<p align=\"justify\">The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4NDIzNSM1MjI5NzA3IzIxMjI0ODE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ODM4N2M2NGItZTcyYy00YjFmLTg1OWMtMjljZjc2NmI4YTk1LTExMzQwNTI=\/tiny\/Medicenna-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Further Information\r\n\r\nFor further information about the Company please contact:\r\nElizabeth Williams, Chief Financial Officer, 416-648-5555, ewilliams@medicenna.com\r\n\r\nInvestor Contact\r\n\r\nFor more investor information, please contact:\r\nDan Ferry, Managing Director, LifeSci Advisors, 617-430-7576, daniel@lifesciadvisors.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TORONTO and HOUSTON, Oct. 28, 2022 (GLOBE NEWSWIRE) &#8212; Medicenna Therapeutics Corp. (&#8220;Medicenna&#8221; or \u201cthe Company&#8221;) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that on October 25, 2022, it received a notice (the \u201cNotice\u201d) from the Nasdaq Stock Market LLC (\u201cNasdaq\u201d), stating that the Company is not in compliance with the minimum bid price requirement (&#8220;Minimum Bid Requirement&#8221;) of US$1.00 per share under the Nasdaq Listing Rule 5450(a)(1) based upon the closing bid price of the Company\u2019s common stock for the 30 consecutive business days prior to the date of the Notice. The Notice has no immediate effect on the listing or trading of the Company\u2019s common stock on Nasdaq, and the Company\u2019s operations are not &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-702487","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TORONTO and HOUSTON, Oct. 28, 2022 (GLOBE NEWSWIRE) &#8212; Medicenna Therapeutics Corp. (&#8220;Medicenna&#8221; or \u201cthe Company&#8221;) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that on October 25, 2022, it received a notice (the \u201cNotice\u201d) from the Nasdaq Stock Market LLC (\u201cNasdaq\u201d), stating that the Company is not in compliance with the minimum bid price requirement (&#8220;Minimum Bid Requirement&#8221;) of US$1.00 per share under the Nasdaq Listing Rule 5450(a)(1) based upon the closing bid price of the Company\u2019s common stock for the 30 consecutive business days prior to the date of the Notice. The Notice has no immediate effect on the listing or trading of the Company\u2019s common stock on Nasdaq, and the Company\u2019s operations are not &hellip; Continue reading &quot;Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-28T11:45:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4NDIzNSM1MjI5NzA3IzIxMjI0ODE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement\",\"datePublished\":\"2022-10-28T11:45:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\\\/\"},\"wordCount\":745,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4NDIzNSM1MjI5NzA3IzIxMjI0ODE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\\\/\",\"name\":\"Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4NDIzNSM1MjI5NzA3IzIxMjI0ODE=\",\"datePublished\":\"2022-10-28T11:45:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4NDIzNSM1MjI5NzA3IzIxMjI0ODE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4NDIzNSM1MjI5NzA3IzIxMjI0ODE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/","og_locale":"en_US","og_type":"article","og_title":"Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - Market Newsdesk","og_description":"TORONTO and HOUSTON, Oct. 28, 2022 (GLOBE NEWSWIRE) &#8212; Medicenna Therapeutics Corp. (&#8220;Medicenna&#8221; or \u201cthe Company&#8221;) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that on October 25, 2022, it received a notice (the \u201cNotice\u201d) from the Nasdaq Stock Market LLC (\u201cNasdaq\u201d), stating that the Company is not in compliance with the minimum bid price requirement (&#8220;Minimum Bid Requirement&#8221;) of US$1.00 per share under the Nasdaq Listing Rule 5450(a)(1) based upon the closing bid price of the Company\u2019s common stock for the 30 consecutive business days prior to the date of the Notice. The Notice has no immediate effect on the listing or trading of the Company\u2019s common stock on Nasdaq, and the Company\u2019s operations are not &hellip; Continue reading \"Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-28T11:45:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4NDIzNSM1MjI5NzA3IzIxMjI0ODE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement","datePublished":"2022-10-28T11:45:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/"},"wordCount":745,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4NDIzNSM1MjI5NzA3IzIxMjI0ODE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/","name":"Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4NDIzNSM1MjI5NzA3IzIxMjI0ODE=","datePublished":"2022-10-28T11:45:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4NDIzNSM1MjI5NzA3IzIxMjI0ODE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4NDIzNSM1MjI5NzA3IzIxMjI0ODE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/702487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=702487"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/702487\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=702487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=702487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=702487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}